GLP-1s and Insurance Coverage in 2026

“Does insurance cover it?” has no single answer, because GLP-1 coverage is governed by at least three separate rulebooks — Medicare statute, state Medicaid choices, and whatever your employer bought. What follows sticks to primary and non-commercial sources and date-stamps every claim, because a coverage rule stated without a date is close to worthless. One distinction runs through all of it: coverage for an approved non-obesity indication is largely settled; coverage for weight loss is where the fights are.

Medicare: a statutory wall, with a temporary door

Medicare has been prohibited by law from covering medications when used specifically for weight loss. Part D plans can cover GLP-1s prescribed for another medically accepted indication — type 2 diabetes, cardiovascular risk reduction, or sleep apnea — but not for obesity as such.

CMS proposed reinterpreting that exclusion, then backed off. The contract year 2026 final rule, published in the Federal Register on 15 April 2025, states CMS did “not intend to finalize” several proposals, listing “Part D Coverage of Anti-Obesity Medications (AOMs) and Application to the Medicaid Program” among them. The exclusion stands.

What exists instead is a demonstration. Per KFF’s brief, updated 11 May 2026, the Medicare GLP-1 Bridge covers selected GLP-1s for obesity at a $50 per month copay, running 1 July 2026 to 31 December 2027 (originally scheduled to end 31 December 2026). It covers all formulations of Foundayo and Wegovy, and the KwikPen formulation of Zepbound. Foundayo is orforglipron, Eli Lilly’s oral GLP-1 receptor agonist for weight management; its FDA label carries an effective date of 1 April 2026.

Nothing has repealed Medicare’s weight-loss exclusion. Every route to Medicare-covered obesity treatment in 2026 is a time-limited demonstration built on top of a statute that is still in force.

Who qualifies for the Bridge

KFF’s 29 June 2026 analysis estimated 3.8 million Part D enrollees would have met the criteria in 2023. Eligibility requires a BMI of 35 or more; or 30 or more with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or above; or 27 or more with pre-diabetes, previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease. Beneficiaries must not have filled a Part D GLP-1 prescription in 2026, and must not have type 2 diabetes, obstructive sleep apnea, or MASH — those route through ordinary Part D instead. The $50 copay does not count toward the Part D deductible or the out-of-pocket spending cap.

Medicaid: thirteen states, and the number is falling

Under the Medicaid Drug Rebate Program, states must cover nearly all of a participating manufacturer’s FDA-approved drugs for medically accepted indications — but weight-loss drugs sit in a small group that may be excluded. Coverage for diabetes, cardiovascular disease and sleep apnea indications remains mandatory.

As of January 2026, 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service, down from 16 in October 2025; California, New Hampshire, Pennsylvania and South Carolina have since dropped coverage, and North Carolina dropped it in October 2025 before reinstating it in December.

The cost pressure behind those reversals shows in the spending data: Medicaid gross spending on GLP-1s rose from roughly $1 billion in 2019 to almost $9 billion in 2024, moving from about 1% to over 8% of Medicaid prescription drug spending before rebates. The BALANCE Model is the federal attempt to change that arithmetic — a voluntary CMS Innovation Center model for manufacturers and state Medicaid agencies, running May 2026 to December 2031, under which manufacturers agreed to a $245 net price per 30-day supply for model drugs in 2027 on the Medicare side.

Employer plans: the widest variation of all

For working-age adults this is usually the decisive rulebook. KFF’s 2025 Employer Health Benefits Survey (22 October 2025) found that coverage of GLP-1s used primarily for weight loss tracks firm size closely:

Firm size (workers)	Covers GLP-1s for weight loss, 2025
200–999	16%
1,000–4,999	30%
5,000 or more	43% (up from 28% in 2024)

Among firms that do cover them, 34% require enrollees to meet with a dietitian, case manager, or therapist, or to join a lifestyle program, to receive the coverage.

The takeaway

As of August 2026: a federal statute still bars Medicare from covering weight-loss drugs, a temporary $50-copay demonstration expires at the end of 2027, thirteen state Medicaid programs cover obesity treatment and several recently stopped, and employer coverage runs from 16% to 43% by firm size. Coverage for diabetes and other approved indications is far more stable than coverage for weight loss, and that distinction explains most of what looks arbitrary from outside.

No general article can tell you your own plan’s rules — your formulary and prior-authorization criteria are the only authoritative answer. If cost rather than coverage is the binding constraint, see when generic GLP-1 prices might fall and compounded semaglutide: the risks and realities.

Sources

• Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes — final rule, Federal Register, 15 April 2025 (GovInfo)
• What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge — KFF, updated 11 May 2026
• Nearly Four Million Medicare Beneficiaries Met the Eligibility Criteria in 2023 for the Medicare GLP-1 Bridge — KFF, 29 June 2026
• Medicaid Coverage of and Spending on GLP-1s — KFF, 16 January 2026
• 2025 Employer Health Benefits Survey — KFF, 22 October 2025
• FOUNDAYO (orforglipron) prescribing information — openFDA drug label API, label effective 1 April 2026

This is sample content created during site scaffolding. Sources have been attached but each claim still needs verification against them before launch.